[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352893-105":59,"doc-detail-352893-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ntrk-gene-fusions-a-compendium-of-fusion-partners-and-tumor-types","NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types","","NTRK gene fusions act as oncogenic drivers across adult and pediatric cancers, supporting tumor-agnostic precision medicine. TRK inhibitors targeting TRK fusion–driven disease are approved, yet NTRK genes can rearrange with many partner genes, creating diverse TRK fusion proteins and emphasizing the need to identify the specific fusion partner. This review compiles updated descriptive data on NTRK fusion partners and their associated tumor types, informing pan-cancer diagnostic testing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ntrk-gene-fusions-a-compendium-of-fusion-partners-and-tumor-types/352893/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ntrk-gene-fusions-a-compendium-of-fusion-partners-and-tumor-types/352893.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are NTRK gene fusions important for precision medicine?","Question",{"text":112,"@type":113},"NTRK gene fusions are oncogenic drivers in multiple adult and pediatric tumors, making them a pan-cancer target for tumor-agnostic precision medicine.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the NTRK gene fusions identified in this analysis?",{"text":117,"@type":113},"They were identified through literature searches (PubMed), searches of a clinical trials database focused on larotrectinib, and searches of two genomic databases.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the analysis find about the diversity of NTRK fusion partners and tumor types?",{"text":121,"@type":113},"Across 25 tumor types, 358 distinct NTRK gene fusion–tumor pairings were identified, spanning 229 fusion partners overall. Primary CNS tumors showed the highest number of distinct fusions, and ETV6::NTRK3 appeared across the most tumor types.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352893,1790292946,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Review Articles  \nNTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types  \nSoo-Ryum Yang, MD1  ; Matteo Repetto, MD1,2; Erin R. Rudzinski, MD3; Marilyn M. Li, MD, MS4  ; Angshumoy Roy, MD5; Lauren Gutstein, MSEd4; Karen Huang, MS4; Jinhua Wu, PhD4  ; Julia Glade Bender, MD1  ; Nicoletta Brega, MD6  ; Arthur M. Buchberg, PhD7  ;  \nVadim Bernard-Gauthier, PhD8; David S. Hong, MD9 ; Alexander Drilon, MD, PhD1,2  ; and Theodore W. Laetsch, MD4   \nDOI [https://doi.org/10.1200/PO-25-01](https://doi.org/10.1200/PO-25-01)150  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | NTRK gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a target for tumor-agnostic precision medicine. Tropomyosin receptor kinase (TRK) inhibitors are approved by the US Food and Drug Administration for cancers driven by TRK fusions. However, NTRK genes can fuse with many different partner genes, leading to diverse TRK fusion proteins, highlighting the importance of identifying the specific fusion partner with optimal pan-cancer diagnostics. This analysis aims to provide an updated descriptive compendium of NTRK gene fusions. |\n| METHODS | NTRK gene fusions were identified via literature searches (PubMed), a search of a clinical trials database (larotrectinib), and searches of two genomic databases (Memorial Sloan Kettering and Children’s Hospital of Philadelphia) . |\n| RESULTS | In total, 358 distinct NTRK gene fusion-tumor pairings were identified across 25 tumor types. Primary CNS tumors were observed to harbor 86 distinct NTRK gene fusions, followed by sarcomas (n 5 73) . Overall, 229 different fusion partners were identified across tumor types (regardless of NTRK gene). Twentythree fusion partners were found to fuse with >1 NTRK gene across tumor types, while 183 fusion partners were associated with only a single NTRK gene in one tumor type. ETV6::NTRK3 was found in the highest number of different tumor types. |\n| CONCLUSION | This analysis illustrates the diversity of NTRK gene fusion partners across various tumor types and highlights the importance of selecting a pan-tumor fusion-partner agnostic test that can identify both known and novel fusion partners to identify patients who may benefit from treatment with TRK inhibitors. |\n\nACCOMPANYING CONTENT  \n Data Supplement  \nAccepted March 20, 2026 Published May 6, 2026  \nJCO Precis Oncol 10:e2501150 © 2026 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe transmembrane tropomyosin receptor kinase (TRK) family is characterized by tyrosine phosphorylation activity after extracellular binding to neurotrophin growth factors, which activates downstream mitogen-activated protein kinase, phosphoinositide 3-kinase, and rat sarcoma viral oncogene homolog intracellular signaling.1 ,2 The TRK kinases TRKA, TRKB, and TRKC are encoded by the NTRK family of genes composed of NTRK1 , NTRK2 , and NTRK3 , respectively.1 Physiologic signaling of TRKA, TRKB, and TRKC is involved in the development and function of the nervous system, while pathologic TRK activity arising from somatic structural variants to NTRK1/2/3 genes can induce aberrant expression and/or activation of TRK.1  \nPathogenic gene fusions involving NTRK genes occur when the 3 9 region of a NTRK gene and the 5 9 end of an upstream partner gene join through intrachromosomal or interchromosomal rearrangement, resulting in an in-frame fusion protein that retains the catalytic tyrosine kinase domain of the NTRK gene.3 The kinase domain of the NTRK gene fusion is then constitutively activated in a ligand-independent fashion, leading to cell proliferation and tumor growth.3  \nNTRK gene fusions are oncogenic drivers for a variety of adult and pediatric tumors, making them a pan-cancer target for precision medicine.3 Overall, NTRK gene fusions have been reported in high frequencies (up to 90%) in rare tumors such as infantile fibrosarcoma and secr","cbCainsP4QrcyUh3","https://ap.wps.com/l/cbCainsP4QrcyUh3","pdf",4413922,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"Why are NTRK gene fusions important for precision medicine?\",\"answer\":\"NTRK gene fusions are oncogenic drivers in multiple adult and pediatric tumors, making them a pan-cancer target for tumor-agnostic precision medicine.\"},{\"question\":\"How were the NTRK gene fusions identified in this analysis?\",\"answer\":\"They were identified through literature searches (PubMed), searches of a clinical trials database focused on larotrectinib, and searches of two genomic databases.\"},{\"question\":\"What did the analysis find about the diversity of NTRK fusion partners and tumor types?\",\"answer\":\"Across 25 tumor types, 358 distinct NTRK gene fusion–tumor pairings were identified, spanning 229 fusion partners overall. Primary CNS tumors showed the highest number of distinct fusions, and ETV6::NTRK3 appeared across the most tumor types.\"}]","NTRK Gene Fusions: A Compendium of Fusion Partners and Tumor Types | PDF",1790101913,25]